FL
NBIX icon

Fort LP’s Neurocrine Biosciences NBIX Stock Holding History

Fort LP’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,118
Closed -$299K – 303
2021
Q3 		$299K Sell
3,118
-2,896
-48% -$274K 0.1% 271
2021
Q2 		$585K Sell
6,014
-3,473
-37% -$333K 0.17% 218
2021
Q1 		$923K Sell
9,487
-466
-5% -$48.9K 0.26% 193
2020
Q4 		$954K Buy
9,953
+3,575
+56% +$345K 0.28% 190
2020
Q3 		$613K Buy
+6,378
New +$738K 0.26% 174
2020
Q2 		– Sell
-223
Closed -$19K – 311
2020
Q1 		$19K Buy
+223
New +$21.8K ﹤0.01% 358

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fort LP's NBIX Position: Q4 2021 in Review

Fort LP sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 3,118 shares — an estimated $299K sold.

Fort LP first reported a position in NBIX in Q1 2020 and held it in 6 quarters. The position peaked at $954K in Q4 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • Fort LP reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
  • Fort LP sold 3,118 Neurocrine Biosciences shares in Q4 2021, an estimated $299K.
  • Fort LP first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 6 quarters.
  • Fort LP's Neurocrine Biosciences position peaked at $954K in Q4 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Fort LP's 13F filing for Q4 2021, filed 11 Feb 2022.